About Us
A little bit about us The Shoalhaven Medical Association was founded over 50 years ago. The purpose of the Shoalhaven Medical Association Incorporated is to enhance healthcare provided to the Shoalhaven community.It does this by supporting medical education and professional networking opportunities for the Shoalhaven’s medical professionals and trainees. We are an independent, not for …
READ MORE
Schedule
- Bill & Pat Ryan Memorial Session
- Morning Session
- Afternoon Session
- Main Meeting Room
Healthcare is increasingly embracing the concept of AI for administrative support with tools such as scribes and AI scanning. The next horizon is AI clinical knowledge.
Patients arrive with AI-generated diagnoses, treatment suggestions and questions, while clinicians can now use AI to retrieve evidence, resolve clinical questions, interpret information, support communication and reduce the cognitive burden of increasingly complex care.
Using practical clinical case studies, this presentation will explore where AI knowledge tools can genuinely support clinicians today, from answering an in-consultation question
and checking management against trusted evidence, to providing evidence based responses to social media misinformation. It will also examine the risks and limitations of current approaches, including hallucination, bias, incomplete clinical context, over-reliance and the challenge of knowing when an apparently authoritative answer can actually be trusted.
Finally, we will look ahead to the emerging concept of the AI clinical companion: technology that can understand clinical context, surface relevant evidence, identify gaps and support safer, more efficient care while keeping clinical judgement and the doctor-patient relationship firmly at the centre.
Come, learn what works and what does not: behind the veil of cosmetic and procedural dermatology. From the perspective of a general dermatologist who dips a toe into the cosmetic world, I hope to enlighten you on evidence based cosmetic topicals, injectables and procedures. Staying on top of clinical evidence helps us fight social media misinformation and give our patients the best possible care.
- Main Meeting Room
Pharmacogenomics is transforming clinical practice by enabling medication choices tailored to an individual’s genetic profile.
This presentation will explore how pharmacogenomic testing is improving prescribing, reducing adverse drug reactions, and enhancing treatment effectiveness across clinical settings. Attendees will gain practical insights into applications relevant to primary care and specialist practice, including evidence, implementation challenges, regulatory considerations, and quality assurance.
The session will also examine emerging developments in genomics, artificial intelligence, and precision medicine.
Beyond their effects on glycaemia and weight, clinical trial data demonstrate that these agents provide broader health benefits, including reductions in major adverse cardiovascular events and heart failure risk, as well as benefits in metabolic dysfunction-associated steatotic liver
disease. Emerging evidence also suggests improvements in obstructive sleep apnoea and knee osteoarthritis symptoms.
This presentation will review the evidence supporting these benefits and discuss practical considerations for incorporating these therapies into contemporary clinical practice and patient management.
- Main Meeting Room
Melanoma care has undergone significant change since the introduction of immunotherapy and targeted therapies. Surgery remains central to diagnosis, local and regional disease control, and selected management of metastatic disease, however systemic treatments increasingly influence
the timing, extent and intent of operative intervention.
This presentation will review recent advances in Melanoma management, highlighting contemporary surgical approaches across the melanoma treatment pathway, and offer practical referral and multidisciplinary decision-making considerations for non-specialists.
Chronic kidney disease (CKD) is a prevalent condition that significantly affects patients, families, and healthcare systems. Often progressing silently until advanced stages, CKD increases the risk of kidney failure, dialysis, and transplantation. Modern management centres on four key pharmacological therapies: renin-angiotensin system inhibitors, sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and nonsteroidal mineralocorticoid receptor antagonists. Large clinical trials demonstrate that these therapies can substantially slow CKD
progression, delaying or potentially preventing kidney failure and dialysis.
In this presentation, Dr Siba Dolai will explore the evolving science of the gut microbiome, dysbiosis and microbiota-based therapies. He will trace faecal microbiota transplantation from an experimental concept to a regulated biological therapy manufactured under GMP conditions.
The talk will cover its established role in recurrent C.difficile infection, emerging applications in IBS, Ulcerative Colitis and Crohn’s Disease, and exciting new research in neurodegenerative and mental health conditions.
